Biogen Idec Reaches New 52-Week High (BIIB)

NEW YORK ( TheStreet) -- Biogen Idec (Nasdaq: BIIB) hit a new 52-week high Wednesday as it is currently trading at $130.50, above its previous 52-week high of $130 with 356,611 shares traded as of 10:45 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Biogen Idec has a market cap of $30.04 billion and is part of the health care sector and drugs industry. Shares are up 16.1% year to date as of the close of trading on Tuesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 25, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Biogen Idec Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI